Complete Pathological Response in Stage IV Rectal Carcinoma: Proper Planning and Place is a Key

Deep Lamichhane, Suraj Suwal, Resham Rana, Shweta Baral, Rishikesh Narayan Shrestha

Abstract


Introduction: Liver metastasis is frequently encountered in patients with rectal cancer; it can be synchronous or metachronous. Some selected patients can be treated with curative intent using multimodality therapy under the care of a dedicated team in a comprehensive cancer center. However, the treatment is long and tiring for the treating team, the patient, and the relatives. Treatment is difficult to execute in a country like ours with a limited number of cancer centers. We present a patient from a remote village with stage IV disease, who completed all modalities of treatment with a favorable outcome.

 

Case Presentation: A fifty-five-year-old man from a remote village presented to us with a complaint of per rectal bleeding. He was diagnosed with rectal carcinoma with solitary liver metastases. He received multimodality treatment in the form of chemotherapy, radiotherapy, and surgery. He attained a complete pathological response at both primary and metastatic sites.

Conclusions: Good outcomes can be achieved in selected stage IV rectal cancer. This requires multimodality treatment and a proper plan, preferably in a comprehensive cancer center

 


Keywords


complete pathological response, liver metastasis, rectal cancer

References


Van der Geest LGM, Lam-Boer J, Koopman M, et

al. Nationwide trends in incidence, treatment and

survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015 Jun;32(5):457–65.

Van der Pool AEM, Damhuis RA, Ijzermans JNM, et

al. Trends in incidence, treatment and survival of

patients with stage IV colorectal cancer: a population-based series. Colorectal Dis Off J Assoc Coloproctology G B Irel. 2012 Jan;14(1):56–61.

Kanas GP, Taylor A, Primrose JN, et al. Survival after

liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin

Epidemiol. 2012;4:283–301. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309–18; discussion 318–21.

Adam R, de Gramont A, Figueras J, et al. Managing

synchronous liver metastases from colorectal cancer:

a multidisciplinary international consensus. Cancer

Treat Rev. 2015 Nov;41(9):729–41.

Weledji EP. Centralization of Liver Cancer Surgery

and Impact on Multidisciplinary Teams Working on

Stage IV Colorectal Cancer. Oncol Rev. 2017 Jun 14;11(2):331.

Oxenberg J, Papenfuss W, Esemuede I, et al.

Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable

treatment changes: a prospective study of 149 consecutive patients. Ann Surg Oncol. 2015 May;22(5):1533–9.

Sauer R, Liersch T, Merkel S, et al. Preoperative

versus postoperative chemoradiotherapy for locally

advanced rectal cancer: results of the German CAO/

ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Jun 1;30(16):1926–33.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO

consensus guidelines for the management of patients

with metastatic colorectal cancer. Ann Oncol Off J

Eur Soc Med Oncol. 2016 Aug;27(8):1386–422.

Sabanathan D, Eslick GD, Shannon J. Use of Neoadjuvant Chemotherapy Plus Molecular Targeted

Therapy in Colorectal Liver Metastases: A Systematic

Review and Meta-analysis. Clin Colorectal Cancer. 2016 Dec;15(4):e141–7.

Krell RW, D’Angelica MI. Treatment sequencing for

simultaneous colorectal liver metastases. J Surg Oncol. 2019 Apr;119(5):583-593.

Maas M, Nelemans PJ, Valentini V, et al. Long-term

outcome in patients with a pathological complete

response after chemoradiation for rectal cancer: a

pooled analysis of individual patient data. Lancet

Oncol. 2010 Sep;11(9):835–44.


Full Text: PDF

DOI: 10.33371/ijoc.v16i2.880

Article Metrics

Abstract view : 118 times
PDF - 35 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.